MX6A Stoklara Genel Bakış Bir yatırım holding şirketi olan Grand Pharmaceutical Group Limited, farmasötik preparatlar ve tıbbi cihazlar, biyoteknoloji ve sağlık ürünleri ve farmasötik hammaddelerin araştırma ve geliştirme, üretim ve satışını yapmaktadır. Daha fazla detay
Ödüller Risk Analizi Tüm Risk Kontrollerini Gör Düşüncelerinizi, bağlantılarınızı ve şirket anlatımınızı yakalayın
Grand Pharmaceutical Group Limited Rakipler Fiyat Geçmişi ve Performans
Hisse fiyatlarındaki yükseliş, düşüş ve değişimlerin özeti Grand Pharmaceutical Group Tarihsel hisse senedi fiyatları Güncel Hisse Fiyatı HK$0.53 52 Haftanın En Yüksek Seviyesi HK$0.62 52 Haftanın En Düşük Seviyesi HK$0.38 Beta 0.74 1 Aylık Değişim -6.25% 3 Aylık Değişim -0.94% 1 Yıllık Değişim n/a 3 Yıllık Değişim -20.45% 5 Yıllık Değişim n/a Halka arzdan bu yana değişim -25.85%
Son Haberler & Güncellemeler
Grand Pharmaceutical Group Limited Submits New Drug Application for the Global Innovative Product GPN01768 to the National Medical Products Administration of the People's Republic of China Dec 16
Grand Pharmaceutical Group Limited's Global Innovative Intravascular Dual-Mode Imaging System NovasyNC Receives Registration Certificate for Medical Device by National Medical Products Administration of the People's Republic of China Dec 12
Telix Pharmaceuticals Limited and Grand Pharmaceutical Group Limited Announces First Patient Dosed in Phase III ZIRCON-CP Trial of TLX250-CDx for Kidney Cancer Imaging in Chinese Patients Nov 28
Grand Pharmaceutical Group Limited and Nanjing Kainite Medical Technology Company Limited Announce First Adjustable Intracranial Stent Retriever Product Produce in China Approve for Commercialization by NMPA Oct 22
National Medical Products Administration Accepts Grand Pharmaceutical Group Limited's Phase III Clinical Study Application of ITM-11 Oct 14
First half 2024 earnings released: EPS: HK$0.44 (vs HK$0.29 in 1H 2023) Sep 27 Daha fazla güncelleme görün
Grand Pharmaceutical Group Limited Submits New Drug Application for the Global Innovative Product GPN01768 to the National Medical Products Administration of the People's Republic of China Dec 16
Grand Pharmaceutical Group Limited's Global Innovative Intravascular Dual-Mode Imaging System NovasyNC Receives Registration Certificate for Medical Device by National Medical Products Administration of the People's Republic of China Dec 12
Telix Pharmaceuticals Limited and Grand Pharmaceutical Group Limited Announces First Patient Dosed in Phase III ZIRCON-CP Trial of TLX250-CDx for Kidney Cancer Imaging in Chinese Patients Nov 28
Grand Pharmaceutical Group Limited and Nanjing Kainite Medical Technology Company Limited Announce First Adjustable Intracranial Stent Retriever Product Produce in China Approve for Commercialization by NMPA Oct 22
National Medical Products Administration Accepts Grand Pharmaceutical Group Limited's Phase III Clinical Study Application of ITM-11 Oct 14
First half 2024 earnings released: EPS: HK$0.44 (vs HK$0.29 in 1H 2023) Sep 27
New minor risk - Share price stability Sep 19
Grand Pharmaceutical Group Limited Appoints Lam Chit Yee Jessica as Executive Director Aug 27
First half 2024 earnings released: EPS: HK$0.44 (vs HK$0.29 in 1H 2023) Aug 22
Grand Pharmaceutical Group Limited Provides Consolidated Earnings Guidance for the Six Months Ended 30 June 2024 Aug 15
Grand Pharmaceutical Group Limited to Report First Half, 2024 Results on Aug 19, 2024 Aug 09
Grand Pharmaceutical Group Limited Announces Executive Changes Jun 24
Grand Pharmaceutical Group Limited Announces the Phase I Clinical Study Conducted in China of the Groups Global Innovative Ophthalmic Drug Gpn00884 Has Completed the First Patient Enrollment Jun 13
Grand Pharmaceutical Group Limited Approves Final Dividend for the Year Ended 31 December 2023 Jun 05
Upcoming dividend of HK$0.26 per share May 30
Grand Pharmaceutical Group Limited, Annual General Meeting, Jun 04, 2024 Apr 29
Grand Pharmaceutical Group Limited, Annual General Meeting, Jun 04, 2024 Apr 28
Executive Chairman recently bought €44k worth of stock Apr 26
Dividend of HK$0.26 announced Mar 25 Grand Pharmaceutical Group Limited Proposes Ordinary Final Cash Dividend for the Year Ended 31 December 2023, Payable on 27 June 2024 Mar 21
Full year 2023 earnings released: EPS: HK$0.54 (vs HK$0.59 in FY 2022) Mar 20
Grand Pharmaceutical Group Limited to Report Fiscal Year 2023 Results on Mar 19, 2024 Mar 08
Grand Pharmaceutical Group Limited Announces Update on Global Innovative Ophthalmic Drug GPN00884 Mar 07
Less than half of directors are independent Feb 07
Grand Pharmaceutical Group Limited Announces the Investigational New Drug Application in China of the Group's Global Innovative Ophthalmic Drug GPN00884 Was Accepted by NMPA Dec 27
Less than half of directors are independent Dec 16
Grand Pharmaceutical Group Limited Announces the Investigational New Drug Application of ARC01 (A002) Nov 03
Grand Pharmaceutical Group Limited Announces Phase III Clinical Trial in China of the Groups Global Innovative Ophthalmic Drug GPN00833 Has Completed the First Patient Enrollment and Dosing Oct 25
Grand Pharmaceutical Group Limited Announces Phase III Clinical Study in China of the Group's Global Innovation Drug RYaltris® Compound Nasal Spray Has Completed and Successfully Met Primary Endpoint Sep 14
Grand Pharmaceutical Group Limited Announces That the Phase I Clinical Trial of Apad, A Global Innovative Drug Independently Developed by the Group for the Treatment of Sepsis, Has Completed First Subject Enrollment and Dosing Approved Recently Aug 18
First half 2023 earnings released: EPS: HK$0.29 (vs HK$0.20 in 1H 2022) Aug 13
Grand Pharmaceutical Group Limited Announces New Mra Drug of the Group Eplerenone Tablets Was Granted Drug Registration Certificate Aug 04
Grand Pharmaceutical Group Limited to Report First Half, 2023 Results on Aug 10, 2023 Aug 01
Grand Pharmaceutical Group Limited Announces Approval by National Medical Products Administration to Conduct Phase II Clinical Study in China Jul 18
Less than half of directors are independent Jul 12
Grand Pharmaceutical Group Limited Appoints Yang Guang as an Executive Director Jul 01
Grand Pharmaceutical Group Limited Announces Resignation of Niu Zhanqi as Executive Director Jun 22
Less than half of directors are independent Jun 08 Grand Pharmaceutical Group Limited Announces Board Changes
Upcoming dividend of HK$0.14 per share at 2.8% yield Jun 02
Less than half of directors are independent May 18 Grand Pharmaceutical Group Limited Announces the Multicenter Phase III Clinical Trial of Ryaltris Compound Nasal Spray
Full year 2022 earnings released: EPS: HK$0.59 (vs HK$0.68 in FY 2021) Mar 23 National Medical Products Administration of the People's Republic of China Accepts Grand Pharmaceutical Group Limited's Investigational New Drug Applications of the Group Three Innovative Products in China
Grand Pharmaceutical Group Limited Conducts Clinical Trials of its Innovative Oral Small Molecule 3Cl Protease Inhibitor GS221 Against COVID-19 Dec 29
Less than half of directors are independent Nov 16
Grand Pharmaceutical Group Limited Announces NMPA Approves Clinical Trial Application in China for Global Innovative Radionuclide-Drug Conjugate TLX591-CDx Oct 18
First half 2022 earnings released: EPS: HK$0.20 (vs HK$0.34 in 1H 2021) Sep 29
Grand Pharmaceutical Group Limited Announces Clinical Trial Application in China for Global Innovative Radionuclide-Drug Conjugate TLX250-CDX Approved by NMPA Sep 29
Less than half of directors are independent Aug 23
First half 2022 earnings released Aug 11
Grand Pharmaceutical Group Limited Provides Unaudited Earnings Guidance for Six Months Ended 30 June 2022 Aug 06
Grand Pharmaceutical Group Announces Clinical Trial Applications in China for Global Innovative Radionuclide-Drug Conjugates TLX591-CDX AND TLX250-CDX Accepted by NMPA Aug 02
Grand Pharmaceutical Group Limited to Report First Half, 2022 Results on Aug 10, 2022 Jul 30
Less than half of directors are independent Jul 07
Executive Director recently bought €64k worth of stock Jun 10
Grand Pharmaceutical Group Limited Declares Final Dividend for the Year Ended 31 December 2021 May 28
Less than half of directors are independent May 02
Grand Pharmaceutical Group Limited Announces Phase III Clinical Trial of Global Innovative Drug Ryaltris Compound Nasal Spray Successfully Completed the First Patient Enrollment in China Apr 08
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Mar 18
Now 21% undervalued after recent price drop Feb 23
Sirtex Medical and Grand Pharmaceutical Group Limited Receive NDA Approval of SIR-Spheres® Y-90 Resin Microspheres in China from the National Medical Products Administration Feb 10
First half 2021 earnings released: EPS HK$0.34 (vs HK$0.21 in 1H 2020) Sep 25
First half 2021 earnings released: EPS HK$0.34 (vs HK$0.21 in 1H 2020) Aug 12
China Grand Pharmaceutical and Healthcare Holdings Limited (SEHK:512) agreed to acquire 22.2% interest in CoRISMA MCS Systems, Inc for $12 million. Aug 08
Less than half of directors are independent Jul 27 Hissedar Getirileri MX6A DE Pharmaceuticals DE Pazar 7D 0% 1.7% 3.0% 1Y n/a -14.4% 12.8%
Hissedar getirilerinin tamamını görün
Getiri vs. Endüstri: MX6A un German Pharmaceuticals sektörüne göre nasıl performans gösterdiğini belirlemek için yeterli veri yok.
Getiri vs Piyasa: MX6A un German Piyasasına göre nasıl performans gösterdiğini belirlemek için yeterli veri yok.
Fiyat Oynaklığı Is MX6A's price volatile compared to industry and market? MX6A volatility MX6A Average Weekly Movement 10.1% Pharmaceuticals Industry Average Movement 5.5% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.5% 10% least volatile stocks in DE Market 2.4%
İstikrarlı Hisse Senedi Fiyatı: MX6A hisse senedi fiyatı, son 3 ayda German piyasasına kıyasla dalgalı seyretti.
Zaman İçindeki Volatilite: MX6A 'nin haftalık oynaklığı ( 10% ) geçen yıl boyunca sabit kaldı, ancak hala German hisselerinin %75'inden yüksek.
Şirket Hakkında Bir yatırım holding şirketi olan Grand Pharmaceutical Group Limited, farmasötik preparatlar ve tıbbi cihazlar, biyoteknoloji ve sağlık ürünleri ve farmasötik hammaddelerin araştırılması ve geliştirilmesi, üretimi ve satışı ile ilgilenmektedir. Şirket, solunum, oftalmoloji, serebro-kardiyovasküler acil ve biyoteknoloji ile ilgili ürünler sunmaktadır. Farmasötik, taurin, zirai kimyasallar, kimyasal ilaç ve amino asit serisi ürünler üretmekte ve satmaktadır.
Daha fazla göster Grand Pharmaceutical Group Limited Temel Bilgiler Özeti Grand Pharmaceutical Group'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır? MX6A temel i̇stati̇sti̇kler Piyasa değeri €1.93b Kazançlar(TTM ) €300.34m Gelir(TTM ) €1.32b
Kazanç ve Gelir En son kazanç raporundan temel karlılık istatistikleri (TTM) MX6A gelir tablosu (TTM ) Gelir HK$10.59b Gelir Maliyeti HK$4.34b Brüt Kâr HK$6.25b Diğer Giderler HK$3.84b Kazançlar HK$2.41b
Temettüler
5.9% Mevcut Temettü Verimi
Şirket Analizi ve Finansal Veri Durumu Veri Son Güncelleme (UTC saati) Şirket Analizi 2025/01/20 16:44 Gün Sonu Hisse Fiyatı 2025/01/17 00:00 Kazançlar 2024/06/30 Yıllık Kazançlar 2023/12/31
Veri Kaynakları Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC 'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
Paket Veri Zaman Çerçevesi Örnek ABD Kaynağı * Şirket Finansalları 10 yıl Gelir tablosu Nakit akış tablosu Bilanço Analist Konsensüs Tahminleri +3 yıl Finansal tahminler Analist fiyat hedefleri Piyasa Fiyatları 30 yıl Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler Sahiplik 10 yıl En büyük hissedarlar İçeriden öğrenenlerin ticareti Yönetim 10 yıl Liderlik ekibi Yönetim Kurulu Önemli Gelişmeler 10 yıl
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube' da eğitimlerimiz bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.
Analist Kaynakları Grand Pharmaceutical Group Limited 7 Bu analistlerden 4, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
Analist Kurum Yanyin Zhu China International Capital Corporation Limited Xiao Wei Lin Everbright Securities Co. Ltd. Yiling Chen Guosen Securities Co., Ltd.
Göster 4 daha fazla analist 